- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Evan Morris, Roche
S
Evan Morris
VP, Government Affairs and Public Policy, Roche
SECRET TO SUCCESS: "It's what you know, not who you know"
SECRET: "I'm a crummy golfer"
After training at DC's policy-and-lobbying powerhouse Patton Boggs, self-described "food and drug lawyer" Evan Morris joined Roche—and the industry—in January 2005. Having watched his mom beat breast cancer, he was inspired to play on the pharma team. "That was before FDA became managed through Congress," he says by way of acknowledging his baptism by partisan fire. Morris has led Roche's Washington office in negotiating policy for flu preparedness, hep C access, and Medicare and Medicaid. The just-barely-thirtysomething Morris is already an old hand inside the beltway. A White House intern at 18, he learned a lasting lesson from his boss, the deputy chief of staff: "'Speak truth to power, no matter how powerful the individual or how ugly the truth.' At the end of the day, that's how I want to be known."
Evan Morris
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
